Lifestyle intervention in obese infertile women

van Oers, Anne Maria

Effect of a lifestyle intervention in obese infertile women on cardiometabolic health and quality of life: A randomized controlled trial

Lotte van Dammen[¶], Vincent Wekker[¶], Anne M. van Oers, Meike A.Q. Mutsaerts, Rebecca C. Painter, Aeilko H. Zwinderman, Henk Groen, Cornelieke van de Beek, Anneke C. Muller Kobold, Jolande A. Land, Walter K.H. Kuchenbecker, Ron van Golde, Gerrit J.E. Oosterhuis, Niels E.A. Vogel, Ben W.J. Mol, Tessa J. Roseboom and Annemieke Hoek on behalf of the LIFEstyle study group

[¶]These authors contributed equally to this work.

Submitted

5

Abstract

Background The prevalence of obesity, an important cardiometabolic risk factor, is rising in women. Lifestyle improvements are the first step in treatment of obesity, but the success depends on factors like timing and motivation. Women are especially receptive to advice about lifestyle before and during pregnancy. Therefore, we hypothesize that the pre-pregnancy period provides the perfect window of opportunity to improve cardiometabolic health and quality of life of obese infertile women, by means of a lifestyle intervention.

Methods and Findings Between 2009-2012, 577 infertile women between 18 and 39 years of age, with a Body Mass Index of ≥ 29 kg/m2, were randomized to a six month lifestyle intervention preceding infertility treatment, or to prompt infertility treatment. The goal of the intervention was 5-10% weight loss or a BMI < 29 kg/m^2. Cardiometabolic outcomes included weight, waist- and hip circumference, body mass index, systolic and diastolic blood pressure, fasting glucose and insulin, HOMA-IR, hs-CRP, lipids and metabolic syndrome. All outcomes were measured by research nurses at randomization, 3 and 6 months. Self-reported quality of life was also measured at 12 months. Three participants withdrew their informed consent, and 63 participants discontinued the intervention program. Mixed effects regression models analyses were performed.

Results Results are displayed as estimated mean differences between intervention and control group. Weight (-3.1 kg 95% CI: -4.0 - -2.2 kg; P < .001), waist circumference (-2.4 cm 95% CI: -3.6 - -1.1 cm; P < .001), hip circumference (-3.0 95% CI: -4.2 - -1.9 cm; P < .001), BMI (-1.2 kg/m^2 95% CI: -1.5 - -0.8 kg/m^2; P < .001), systolic blood pressure (-2.8 mmHg 95% CI: -5.0 - -0.7 mmHg; P = .01) and HOMA-IR (-0.5 95% CI: -0.8 - -0.1; P = .01) were lower in the intervention group compared to controls. Hs-CRP and lipids did not differ between groups. The odds ratio for metabolic syndrome in the intervention group was 0.53 (95% CI: 0.33-0.85; P < .01) compared to controls. Physical QoL scores were higher in the lifestyle intervention group (2.2 95% CI: 0.9 - 3.5; P = .001) while mental QoL scores did not differ.

Conclusions In obese infertile women, a lifestyle intervention prior to infertility treatment improves cardiometabolic health and self-reported physical quality of life (LIFEstyle study: Netherlands Trial Register: NTR1530).

Introduction

Cardiometabolic disease is the leading cause of death in women worldwide. In the United States, cardiometabolic diseases are responsible for more than 25% of mortality in women.[1] In the last forty years, the global age standardized prevalence of obesity in women, as one of the major modifiable risk factors for cardiometabolic diseases, has more than doubled; from 6.4% (5.1 to 7.8) in 1975 to 14.9% (13.6 to 16.1) in 2014.[2] The prevalence of obesity among women of childbearing age is even higher: 16.4% in 2009. Obesity reduces fertility[3,4] and increases the risk of atherosclerosis, hypertension, dyslipidemia, chronic inflammation, and insulin resistance.[5,6] The combination of these cardiometabolic risk factors is also being referred to as metabolic syndrome (MetS).[7,8] In women, MetS doubles the risk of cardiovascular mortality.[9,10] Both cardiometabolic and reproductive morbidity reduce physical and mental quality of life (QoL).[11,12]

Current international guidelines state that lifestyle improvements are the cornerstone of primary prevention and treatment of obesity and cardiometabolic diseases.[13,14] Lifestyle improvements are difficult for patients to realize and the effects on weight reduction and retention are disappointing.[15] The success of a lifestyle intervention depends on several factors including intrinsic motivation, but also timing, duration, and intensity of the intervention are important.[16] In general, women are especially receptive to advice about lifestyle before and during pregnancy. For example, 39% of women who are planning a pregnancy discontinue tobacco smoking, which is almost eight times higher than quitting rates in women not planning a pregnancy.[17,18]

The LIFEstyle study was the first large randomized controlled trial (RCT) to investigate the effects of a six month lifestyle intervention among obese infertile women who intended to become pregnant. The effects of the intervention on reproductive outcomes were published in May 2016.[19] Women in the intervention group had significantly more natural conceptions and a comparable rate of ongoing pregnancies, although there was no increased rate of vaginal birth of a healthy singleton at term. This paper reports the effects on cardiometabolic health and QoL.

Materials and methods

Design

The LIFEstyle study, a multi-center RCT was conducted in 17 general and six academic medical centers across the Netherlands. Participants were included in the study between June 9, 2009, and June 22, 2012. The study was conducted following the principles of the

Declaration of Helsinki and approved by the medical ethics committee of the University Medical Centre Groningen (UMCG) (2008/284), as well as by the board of directors of the other participating hospitals. All included participants gave written informed consent. The trial was registered in the Netherlands Trial Registry (NTR 1530) and the LIFEstyle study protocol has been published.[19,20]

Participants

Infertile women aged between 18 and 39 years, with a BMI of ≥ 29 kg/m^2 were eligible. Infertility was defined as chronic anovulation or as unsuccessful conception for at least 12 months.[21] Women with severe endometriosis, premature ovarian insufficiency, endocrinopathy, untreated preexisting hypertension, or women with a history of hypertension related pregnancy complications were excluded from participating.[20]

Randomization

Participants were randomized 1:1 between a six month lifestyle intervention preceding infertility treatment or prompt infertility treatment. Stratified randomization with an online program was performed at the UMCG according to trial center and ovulatory status.

Lifestyle intervention

The goal of the lifestyle intervention was a 5-10% weight loss or a BMI < 29 kg/m^2 within six months. The dietary therapy, using an online diary, aimed at caloric reduction of 600 kcal, with a minimum intake of 1200 kcal/day.[22] Participants were advised to be physically active on moderate-intensity level for at least two or three times a week. Daily physical activity was stimulated with the use of a pedometer, aimed at 10 000 steps per day. The individualized behavioral modification was focused on creating awareness of lifestyle predisposing to obesity. The lifestyle intervention was in concordance with the recommendations of the National Institute of Health.[23]

The lifestyle intervention consisted of face-to-face sessions of approximately 30 minutes at the outpatient clinics, four in the first three months and two in the last three months and four sessions by telephone or e-mail. The intervention coaches had a background in nursing or nutritional science and were trained to practice motivational counselling techniques.[24] A structured software program was used to minimize the practice variation between the intervention coaches.[25] Participants discontinued the intervention if they became pregnant, but in case of a miscarriage they could re-enter the intervention. Participants who successfully reached the goal of the lifestyle intervention could proceed with their indicated infertility treatment before they had finished the six month intervention.[26] If women missed two or more consecutive sessions, they were considered to have not completed the intervention.

Control strategy

Participants allocated to the control group were treated promptly in accordance with Dutch infertility guidelines, irrespective of their BMI.[26] Anovulatory women started with ovulation induction with clomiphene citrate. If pregnancy did not occur in six to 12 cycles or if women developed clomiphene resistance, gonadotropin therapy was initiated in a low-dose step-up regimen for a maximum of 12 cycles.[27] In ovulatory women, treatment depended on the estimated probability of natural conception according to the Hunault prediction model.[28] If the probability was estimated to be < 30%, women were offered up to six cycles of intrauterine insemination (IUI). If the probability was estimated to be > 30%, expectant management was proposed for six to 12 months. In vitro fertilization was initiated in women with tubal disease or after IUI had failed. Intracytoplasmic sperm injection was used in couples with severe male-factor infertility.

Patient involvement

A single center pilot study had been performed previously to evaluate the intervention. During this pilot study, it became clear that patients preferred individual sessions with evaluation of personal goals instead of group sessions, because individual care was considered less time consuming. Otherwise, patients were not involved in the design nor in the conduct of the LIFEstyle study. The Dutch patient support group 'Freya' invited their peers on their website to participate in the trial. Participants received a personal letter with the results of the trial in layman's terms.

Outcome measures

The prespecified outcomes were weight, BMI (weight in kg divided by height in m^2), waist- and hip circumference and ratio, systolic and diastolic blood pressure, fasting serum concentrations of glucose and insulin, and QoL. Insulin resistance was quantified using the homeostasis model assessment of insulin resistance (HOMA-IR). This model was defined as fasting insulin concentration in μU/mL multiplied by fasting glucose concentration in mmol/L divided by 22.5.[29]

Non-prespecified outcomes were fasting serum concentrations of triglycerides, total cholesterol, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), and high sensitive C-reactive protein (hs-CRP). The 2001 revised criteria of the National Cholesterol Education Program ATP III (rNCEP ATP III) were used to identify participants with MetS.[8] The power calculation was based on the primary outcome of the LIFEstyle study: the vaginal birth of a healthy singleton at 37 weeks or more within 24 months. This outcome has been published previously.[19]

Study Procedures

In all non-pregnant participants, during the hospital visits (i.e. at randomization, three and six months), the research nurses measured body weight (kg), height (cm), waist circumference (measured in cm at the narrowest part between the lower rib and iliac crest), hip circumference (measured in cm at the level of the greatest gluteal protuberance), and blood pressure (mmHg, measured manually or electronically in sitting position). Fasting blood samples were collected by venipuncture into one serum and one sodium fluoride vacutainer tube. Serum samples were kept at room temperature for a minimum of 30 minutes for coagulation, and then centrifuged at 1700 x g for 10 minutes at 4 ˚C to obtain serum and plasma, which were stored at -80˚C. The biochemical analyses were performed in the central laboratory of the University Medical Centre Groningen. Hs-CRP was measured with an immuno-turbidimetric assay. Triglycerides, total cholesterol, HDL-C, and LDL-C concentrations were measured using enzymatic colorimetric assays. Fasting plasma glucose was measured with an enzymatic UV test (hexokinase method). All previously described assays were produced by Roche® Modular P (Roche®, Manheim, Germany). Insulin was measured with the Architect manufactured by Abbott Diagnostics (Lake Forest, Illinois, United States), using an chemiluminescent micro particle immunoassay. The intra- and interassay variation was respectively 0.5-4.0% and 1.9-6.2% for hs-CRP; 1.5% and 1.8% for triglycerides; 0.8% and 1.7% for total cholesterol; 0.6-0.95% and 1.2-1.3% for HDL-C; 0.72%-0.81% and 1.03-1.18% for LDL-C; 1.0% and 1.7% for glucose; 2.1-4.1% and 2.4-4.2% for insulin. Participants filled in the Short Form 36 (SF-36) at the time of randomization, and three, six, and 12 months later, using a web-based survey. The SF-36 is a general health related QoL measure, consisting of 36 items.[30] This questionnaire consists of a Physical Component Score (PCS) and a Mental Component Score (MCS), in which higher scores represents a better QoL. The SF-36 is sensitive to changes during lifestyle interventions.[31] The Dutch SF-36 is widely used and has demonstrated good reliability (Cronbach's $\alpha = 0.71 - 0.92$).[32]

Statistical analysis

The analyses were performed on an intention-to-treat basis. Mixed effects regression model analyses were constructed with a random intercept per patient for all outcomes. Fixed effects were follow-up time, randomization group, and their interaction. The baseline measurement was included as a covariate. The dependent variable was the cardiometabolic outcome measure or QoL score. In order to analyze the odds of metabolic syndrome, a generalized linear mixed effects regression model was used. All participants with at least one measurement were included in the analyses (Fig 1). Data collected in pregnant participants, unknown to be pregnant at time of measurement or bloodsampling, were excluded since pregnancy is known to have substantial effects on cardiometabolic outcomes. Awareness of being pregnant may influence QoL, hence QoL data collected more than two weeks

after the conception date was excluded. Since infertility treatment may also influence cardiometabolic health, an additional analysis was performed adjusted for receiving any type of infertility treatment at the time of the visit. Outcomes of the mixed effects regression model analyses are presented as estimated marginal means and 95% confidence intervals (CI). All statistical analyses were performed using IBM SPSS version 22.0 (Armonk, NY, USA).



Fig 1. Flowchart of participants.

Results

In total, 822 women were eligible to participate, of whom 577 women were randomized (Fig 1). Three women withdrew informed consent after randomization, leaving a total of 289 in the intervention group and 285 women in the control group. A total of 63 of the 289 women discontinued the lifestyle intervention, due to lack of motivation (N=40), relationship problems (N=12), or other reasons (N=11). Table 1 shows that the baseline characteristics were similar between the two groups.

Cardiometabolic data was collected at time of randomization, as well as three months (median was 14 (interquartile range 13-15) weeks), and six months (median was 27 (interquartile range 25-30) weeks) after randomization. The effects of the lifestyle intervention on cardiometabolic health, at three and six months, are shown in Table 2. There were no significant interactions between time and randomization group, for all outcomes.

The mean weight in the intervention group over the two follow-up measurements was lower, compared to the control group (-3.1 kg 95% CI: -4.0 to -2.2 kg; $P < 0.001$). BMI was lower in the intervention group compared to the control group, (-1.2 kg/m^2 95% CI: -1.5 to -0.8 kg/m^2; $P < 0.001$). Waist- and hip circumference were lower in the intervention group compared to the control group respectively (-2.4 cm 95% CI: -3.6 to -1.1 cm; $P < 0.001$), and (-3.0 95% CI: -4.2 to -1.9 cm; $P < 0.001$). Waist-hip circumference ratio did not differ between groups. Systolic blood pressure was lower in the intervention group compared to the control group (-2.8 mmHg 95% CI: -5.0 to -0.7 mmHg; $P = 0.01$). Diastolic blood pressure was lower in the intervention group compared to the control group (-1.7 mmHg 95% CI: -3.3 to -0.1 mmHg; $P = 0.04$). In the intervention group hs-CRP was lower compared to the control group, (-0.8 mg/l 95% CI: -1.7 to 0.1 mg/L), but this difference was not statistically significant ($P = 0.07$). Triglycerides did not differ between the control and intervention group. Total cholesterol was lower in the intervention group compared to the control group (-3.9 mg/dL 95% CI: -7.7 - 0.4 mg/dL), but this difference was not statistically significant ($P = 0.09$). There was no difference between the groups in HDL-C . LDL-C was, compared to the control group, lower in the intervention group (-3.9 mg/dL 95% CI: -7.7 - 0.4 mg/dL), although not statistically significant ($P = 0.07$). In the intervention group glucose was lower compared to the control group (-1.8 mg/dL 95% CI: -3.6 to -0.2 mg/dL; $P = 0.04$). Insulin was lower in the intervention group compared to the control group (-11.1 pmol/L 95% CI: -20.1 - -2.8 pmol/L; $P = .01$). In the intervention group HOMA-IR was lower, compared to the control group (-0.5 95% CI: -0.8 to -0.1; $P = 0.01$).

Table 1. Baseline characteristics of study participants in intervention and control group

	Intervention group (N=289)	Control group (N=285)
Age (years; mean; SD)	29.7 (4.5)	29.8 (4.6)
Caucasian (yes; N; %)	256 (88.6)	246 (86.3)
Education (N; %)		
- Primary school (4-12 years)	17 (5.9)	10 (3.5)
- Secondary Education	68 (23.5)	63 (22.1)
- Intermediate Vocational Education	135 (46.7)	131 (46.0)
- Advanced Vocational Education or University	56 (19.4)	69 (24.2)
- Unknown	13 (4.5)	12 (4.2)
Current smoker (yes; N; %)	76 (26.7)	60 (21.1)
Infertility assessment		
- Anovulatory infertility (yes; N; %)	128 (44.3)	141(49.5)
• **Rotterdam 2003 criteria PCOS (yes; N; %)**	97/128 (75.8)	104/141 (73.8)
Anthropometrics		
– Weight (kg; mean; SD)	103.6 (14.0)	103.0 (12.3)
– BMI (kg/m2; mean; SD)	36.1 (3.5)	36.0 (3.4)
– Waist circumference (cm; mean; SD)	108.2 (9.7)	107.9 (9.2)
– Hip circumference (cm; mean; SD)	125.0 (9.0)	125.2 (8.7)
– Waist-hip circumference ratio (mean, SD)	0.87 (0.07)	0.86 (0.07)
Blood pressure		
- Systolic blood pressure (mmHg; mean; SD)	126.1 (14.5)	127.0 (13.4)
- Diastolic blood pressure (mmHg; mean; SD)	79.7 (9.7)	80.1 (8.5)
Biochemical measures		
- Hs-CRP (mg/l; mean; SD)	5.6 (5.0)	5.6 (4.9)
- Triglycerides (mmol/l; mean; SD)	1.2 (0.8)	1.4 (1.6)
- Total cholesterol (mmol/l; mean; SD)	4.8 (0.9)	4.8 (0.9)
- HDL-C (mmol/l; mean; SD)	1.2 (0.3)	1.2 (0.3)
- LDL-C (mmol/l; mean; SD)	3.1 (0.8)	3.1 (0.8)
- Glucose (mmol/l; mean; SD)	5.3 (0.6)	5.4 (0.8)
- Insulin (pmol/L; mean; SD)	96.5 (51.4)	103.5 (62.5)
- HOMA-IR (mean; SD)	3.3 (2.0)	3.6 (2.5)
Metabolic syndrome (Yes; N; %)	121 (52.4)	133 (58.3)
Quality of life		
- Physical quality of life (mean; SD)	49.5 (9.4)	50.3 (9.1)
- Mental quality of life (mean; SD)	50.2 (9.1)	49.0 (10.4)

Abbreviations: BMI, Body Mass Index; PCOS, Polycystic Ovary Syndrome; Hs-CRP, High sensitive C-Reactive Protein; HDL-C, High Density Lipoprotein cholesterol; LDL-C, Low Density Lipoprotein cholesterol; HOMA-IR, Homeostasis Model of Insulin Resistance; N, number; SD, Standard deviation.

Table 2. Outcomes at three and six months for the intervention and control group.

	3 months			6 months		
	Intervention group (N=289)	Control group (N=285)	P value	Intervention group (N=289)	Control group (N=285)	P value
Anthropometrics						
- Weight (kg)	99.9 (0.3)	102.6 (0.3)	< 0.001	98.6 (0.4)	102.2 (0.4)	< 0.001
- BMI (kg/m2)	34.8 (0.1)	35.8 (0.1)	< 0.001	34.3 (0.1)	35.6 (0.1)	< 0.001
- Waist circumference (cm)	104.6 (0.5)	106.3 (0.5)	0.01	102.9 (0.5)	106.3 (0.6)	< 0.001
- Hip circumference (cm)	121.8 (0.4)	124.2 (0.4)	< 0.001	120.4 (0.5)	124.6 (0.5)	< 0.001
- WH ratio	0.86 (0.01)	0.86 (0.01)	0.975	0.86 (0.01)	0.86 (0.01)	0.960
Blood pressure						
- Systolic blood pressure (mmHg)	124.2 (0.9)	126.3 (0.9)	0.096	121.3 (1.0)	125.4 (1.0)	0.005
- Diastolic blood pressure (mmHg)	78.7 (0.6)	79.8 (0.6)	0.219	78.4 (0.7)	81.2 (0.7)	0.009
Biochemical measures						
- Hs-CRP (mg/l)	5.17 (0.38)	5.84 (0.40)	0.223	5.15 (0.45)	6.19 (0.47)	0.303
- Triglycerides (mmol/l)	1.34 (0.05)	1.29 (0.05)	0.470	1.25 (0.06)	1.45 (0.06)	0.012
- Total cholesterol (mmol/l)	4.79 (0.05)	4.79 (0.05)	0.354	4.75 (0.05)	4.90 (0.05)	0.046
- HDL-C (mmol/l)	1.16 (0.01)	1.17 (0.02)	0.624	1.19 (0.02)	1.21 (0.02)	0.346
- LDL-C (mmol/l)	3.02 (0.04)	3.12 (0.04)	0.062	3.08 (0.04)	3.14 (0.05)	0.329
- Glucose (mmol/l)	5.32 (0.05)	5.41 (0.05)	0.160	5.24 (0.05)	5.40 (0.06)	0.040
- Insulin (pmol/L)	89.9 (3.4)	104.6 (3.6)	0.003	89.4 (3.9)	95.4 (4.1)	0.297
- HOMA-IR	3.12 (0.13)	3.72 (0.14)	0.002	3.05 (0.15)	3.27 (0.16)	0.303
Metabolic syndrome (Yes; N; %)	102 (42.6)	137 (57.1)	0.042	79 (33.0)	120 (49.9)	0.036

Notes: Values are estimated means (SE) unless stated otherwise
Abbreviations: BMI, Body Mass Index; Hs-CRP, High sensitive C-Reactive Protein; HDL-C, High Density Lipoprotein cholesterol; LDL-C, Low Density Lipoprotein cholesterol; HOMA-IR, Homeostasis Model of Insulin Resistance; N, number; SD, Standard deviation.

The prevalence of metabolic syndrome at baseline, three, and six months is shown in Fig 2. For women participating in the lifestyle intervention group, the odds ratio for metabolic syndrome was 0.53 (95% CI: 0.33 to 0.85; P < 0.01) compared to women in the control group. As shown in Fig 3, physical QoL scores were higher in the lifestyle intervention group, compared to the control group (2.2 95% CI: 0.9 to 3.5; P = 0.001). Mental QoL scores did not show any differences between groups.

The adjusted models for receiving infertility treatment did not change any of the results (data not shown).



Fig 2. Prevalence of metabolic syndrome, at baseline, 3 and 6 months, by randomization group.



Fig 3. Physical and mental quality of life at baseline, 3, 6, and 12 months, by randomization group.
Abbreviations: QoL, Quality of Life; PCS, Physical Component Score; MCS, Mental Component Score.

Discussion

A six month lifestyle intervention prior to infertility treatment leads to better cardiometabolic health in obese infertile women. Participants in the lifestyle intervention group had lower body weight, waist- and hip circumference, blood pressure, fasting glucose and insulin levels, insulin resistance, and a higher physical QoL compared to women who promptly started infertility treatment. These relatively small but consistent effects on cardiometabolic factors resulted in halved odds of MetS.

Comparison with other studies

The effect of the lifestyle intervention could be considered to have limited clinical relevance because of the modest effects on each of the separate outcomes. However, the effect of the intervention on the composite outcome for MetS is highly clinically relevant, since MetS leads to doubled risks of cardiovascular events and a 50% increase in all-cause mortality.[8,9,33,34] Halving the odds of MetS could potentially greatly diminish the future cardiovascular risk of these women.

The lifestyle intervention led to higher physical QoL, but we did not find any effect on mental QoL. Our finding of higher physical QoL is in concordance with previous weight loss trials.[31] The lack of effect of the intervention on mental QoL might be explained by the fact that women participating in this trial were infertile and their primary motivation for participating in the LIFEstyle study was to become pregnant and not to lose weight. For this reason ongoing infertility could overshadow the potential positive effect of the intervention on mental QoL.

Strengths and limitations

This is the first large multi-center RCT investigating the effects of a lifestyle intervention among obese infertile women. Blinding of participants was not possible, which may have introduced bias. However, we consider it unlikely that the findings are unreliable due to bias as the biochemical outcomes were objectively measured, and the physical outcomes were assessed by research nurses not involved in the lifestyle intervention program. The design of the current RCT has contributed to missing data (Fig 1), as participants who became pregnant during the first six months after randomization were excluded from further physical examination and blood sampling. Data collected during pregnancy were excluded from the statistical analyses because of the possible effects of pregnancy on the cardiometabolic health and QoL.[35,36] Mixed effects regression model analyses were performed to deal with repeated measurements and missing data. This statistical method is able to accommodate all data available for a participant instead of excluding a participant from analysis in case of missing measurements.[37]

Participants in the control group started infertility treatment promptly, which might have affected cardiometabolic outcomes. However, after adjustment for infertility treatment, the effects of the lifestyle intervention on cardiometabolic health did not change. Hence, the effects can be attributed to the lifestyle intervention.

Implications

Based on the results of the LIFEstyle study, obese infertile women should be informed about the positive effects of a lifestyle intervention on their cardiometabolic health and physical QoL. This may increase their intrinsic motivation to adjust lifestyle in the preconceptional period, and may facilitate sustained long-term lifestyle improvement. Moreover, optimizing preconceptional lifestyle could lead to a healthier intrauterine environment, and improve long-term health in the offspring as well.[38-40] To evaluate the long-term effects of lifestyle intervention prior to infertility treatment, we are currently performing the 5-7 year follow-up of the LIFEstyle study in mothers and their offspring.

References

1. Xu J, Murphy S, Kochanek K, Bastian B. Deaths: Final data for 2013. *National Vital Statistics Report.* 2016;64(2).
2. Collaboration NCDRF. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. *The Lancet.* 2016;387(10026):1377-1396.
3. Gesink Law DC, Maclehose RF, Longnecker MP. Obesity and time to pregnancy. *Human Reproduction.* 2007;22(2):414-420.
4. van der Steeg JW, Steures P, Eijkemans MJC, et al. Obesity affects spontaneous pregnancy chances in subfertile, ovulatory women. *Human Reproduction.* 2008;23(2):324-328.
5. Brown CD, Higgins M, Donato KA, et al. Body Mass Index and the Prevalence of Hypertension and Dyslipidemia. *Obesity research.* 2000;8(9):605-619.
6. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. *Nat Rev Cardiol.* 2009;6(6):399-409.
7. Expert Panel on D, Evaluation, and Treatment of High Blood Cholesterol in A. EXecutive summary of the third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii). *JAMA.* 2001;285(19):2486-2497.
8. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation.* 2005;112(17):2735-2752.
9. Mottillo S, Filion KB, Genest J, et al. The Metabolic Syndrome and Cardiovascular Risk: A Systematic Review and Meta-Analysis. *Journal of the American College of Cardiology.* 2010;56(14):1113-1132.
10. Malik S, Wong ND, Franklin SS, et al. Impact of the Metabolic Syndrome on Mortality From Coronary Heart Disease, Cardiovascular Disease, and All Causes in United States Adults. *Circulation.* 2004;110(10):1245-1250.
11. Han JH, Park HS, Shin CI, et al. Metabolic syndrome and quality of life (QOL) using generalised and obesity-specific QOL scales. *International journal of clinical practice.* 2009;63(5):735-741.
12. Hahn S, Janssen OE, Tan S, et al. Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. *European Journal of Endocrinology.* 2005;153(6):853-860.
13. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. *The Journal of Clinical Endocrinology & Metabolism.* 2015;100(2):342-362.
14. Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction. *The American Heart Association's Strategic Impact Goal Through 2020 and Beyond.* 2010;121(4):586-613.
15. Wu T, Gao X, Chen M, Van Dam RM. Long-term effectiveness of diet-plus-exercise interventions vs. diet-only interventions for weight loss: a meta-analysis. *Obesity Reviews.* 2009;10(3):313-323.
16. Roumen C, Blaak EE, Corpeleijn E. Lifestyle intervention for prevention of diabetes: determinants of success for future implementation. *Nutrition Reviews.* 2009;67(3):132.
17. Herzig K, Danley D, Jackson R, Petersen R, Chamberlain L, Gerbert B. Seizing the 9-month moment: Addressing behavioral risks in prenatal patients. *Patient Education and Counseling.* 2006;61(2):228-235.
18. McBride CM, Emmons KM, Lipkus IM. Understanding the potential of teachable moments: the case of smoking cessation. *Health Education Research.* 2003;18(2):156-170.
19. Mutsaerts MAQ, van Oers AM, Groen H, et al. Randomized Trial of a Lifestyle Program in Obese Infertile Women. *New England Journal of Medicine.* 2016;374(20):1942-1953.
20. Mutsaerts M, Groen H, ter Bogt N, et al. The LIFESTYLE study: costs and effects of a structured lifestyle program in overweight and obese subfertile women to reduce the need for fertility treatment and improve reproductive outcome. A randomised controlled trial. *BMC Women's Health.* 2010;10(1):22.
21. Dhont M. WHO-classification of anovulation: background, evidence and problems. *International Congress Series.* 2005;1279:3-9.
22. Voedingscentrum. Mijn eetmeter: scan je dagmenu. (https://mijn.voedingscentrum.nl/nl/eetmeter/).
23. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. *Obesity research.* 1998;6 Suppl 2:51s-209s.

24. Patrick K SJ, Long B, Calfas KJ, Wooten W, Heath G, Pratt M. A new tool for encouraging activity. Project PACE. . *The physician and sportsmedicine.* 1994:45-55.
25. ter Bogt NC, Bemelmans WJ, Beltman FW, Broer J, Smit AJ, van der Meer K. Preventing weight gain: one-year results of a randomized lifestyle intervention. *American journal of preventive medicine.* 2009;37(4):270-277.
26. Su DF, Wang XY. Metformin vs insulin in the management of gestational diabetes: A systematic review and meta-analysis. *Diabetes Research and Clinical Practice.* 2014;104(3):353-357.
27. Consensus on infertility treatment related to polycystic ovary syndrome. *Human Reproduction.* 2008;23(3):462-477.
28. Hunault CC, Habbema JDF, Eijkemans MJC, Collins JA, Evers JLH, te Velde ER. Two new prediction rules for spontaneous pregnancy leading to live birth among subfertile couples, based on the synthesis of three previous models. *Human Reproduction.* 2004;19(9):2019-2026.
29. Matthews DR HJ, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia.* 1985:412-419.
30. Aaronson NK, Muller M, Cohen PD, et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. *Journal of clinical epidemiology.* 1998;51(11):1055-1068.
31. Danielsen KK, Sundgot-Borgen J, Maehlum S, Svendsen M. Beyond weight reduction: improvements in quality of life after an intensive lifestyle intervention in subjects with severe obesity. *Annals of medicine.* 2014;46(5):273-282.
32. VanderZee KI, Sanderman R, Heyink J. A comparison of two multidimensional measures of health status: the Nottingham Health Profile and the RAND 36-Item Health Survey 1.0. *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation.* 1996;5(1):165-174.
33. Cerezo C, Segura J, Praga M, Ruilope LM. Guidelines Updates in the Treatment of Obesity or Metabolic Syndrome and Hypertension. *Current Hypertension Reports.* 2013;15(3):196-203.
34. National Guideline C. Cardiometabolic risk management guidelines in primary care. 2011.
35. Sanghavi M, Rutherford JD. Cardiovascular Physiology of Pregnancy. *Circulation.* 2014;130(12):1003-1008.
36. Sonagra AD, Biradar SM, K D, Murthy D.S J. Normal Pregnancy- A State of Insulin Resistance. *Journal of Clinical and Diagnostic Research : JCDR.* 2014;8(11):CC01-CC03.
37. West BT. Analyzing Longitudinal Data With the Linear Mixed Models Procedure in SPSS. *Evaluation & the Health Professions.* 2009;32(3):207-228.
38. Barker DJP, Osmond C. INFANT MORTALITY, CHILDHOOD NUTRITION, AND ISCHAEMIC HEART DISEASE IN ENGLAND AND WALES. *The Lancet.* 1986;327(8489):1077-1081.
39. Whincup PH, Kaye SJ, Owen CG, et al. Birth weight and risk of type 2 diabetes: A systematic review. *JAMA.* 2008;300(24):2886-2897.
40. Gluckman PD, Hanson MA. Living with the Past: Evolution, Development, and Patterns of Disease. *Science.* 2004;305(5691):1733.